{"id":"NCT02418585","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","officialTitle":"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-07","primaryCompletion":"2017-06-01","completion":"2017-11-06","firstPosted":"2015-04-16","resultsPosted":"2019-04-19","lastUpdate":"2025-04-29"},"enrollment":236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Treatment-resistant Depression"],"interventions":[{"type":"DRUG","name":"Esketamine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Escitalopram (Oral antidepressant)","otherNames":[]},{"type":"DRUG","name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Venlafaxine Extended Release (XR) (Oral Antidepressant)","otherNames":[]}],"arms":[{"label":"Intranasal Esketamine plus oral antidepressant","type":"EXPERIMENTAL"},{"label":"Placebo plus oral antidepressant","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis","timeFrame":"Baseline up to Day 28 of Double-blind Induction Phase","effectByArm":[{"arm":"Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)","deltaMin":-21.4,"sd":12.32},{"arm":"Intranasal Placebo Plus Oral AD","deltaMin":-17,"sd":13.88}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.020"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":48,"countries":["United States","Czechia","Germany","Poland","Spain"]},"refs":{"pmids":["38557430","37158911","37019044","36273682","35441931","35022754","34973081","34510411","34293233","34288609","34235612","33128208","32860422","32367114","31109201"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=CR107147&amp;attachmentIdentifier=512d9c31-6ce0-4e92-b568-a7ef54a494d2&amp;fileName=ESKETINTRD3002_(CR107147)_Additional_results_data_CH.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":115},"commonTop":["Headache","Dysgeusia","Nausea","Dissociation","Vertigo"]}}